←Back to Expert Scholars
Translational Medicine / 转化医学ROS1 Fusion Resistance Mechanisms
Byoung Chul Cho
MD, PhD
🏢Yonsei Cancer Center🌐South Korea
Professor of Medicine
82
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Byoung Chul Cho has been a principal investigator in multiple ROS1-targeted therapy trials in the Asia-Pacific region. He contributed to the TRIDENT-1 trial establishing repotrectinib for ROS1-positive NSCLC including TKI-pretreated patients. His translational research program addresses fusion gene diversity in Asian populations.
Share:
🧪Research Fields 研究领域
ROS1 fusions
Repotrectinib
Asia-Pacific trials
Molecular oncology
Targeted therapy
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Byoung Chul Cho 的研究动态
Follow Byoung Chul Cho's research updates
留下邮箱，当我们发布与 Byoung Chul Cho（Yonsei Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment